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Background: Limited data exist on outcomes for metastatic renal cell carcinoma (mRCC) patients treated with multiple lines of
therapy. Benchmarks for survival are required for patient counselling and clinical trial design.
Methods:Outcomes of mRCC patients from the International mRCC Database Consortium database treated with 1, 2, or 3þ lines
of targeted therapy (TT) were compared by proportional hazards regression. Overall survival (OS) and progression-free survival
(PFS) were calculated using different population inclusion criteria.
Results: In total, 2705 patients were treated with TT of which 57% received only first-line TT, 27% received two lines of TT, and 16%
received 3þ lines of TT. Overall survival of patients who received 1, 2, or 3þ lines of TT were 14.9, 21.0, and 39.2 months,
respectively, from first-line TT (Po0.0001). On multivariable analysis, 2 lines and 3þ lines of therapy were each associated with
better OS (HR¼ 0.738 and 0.626, Po0.0001). Survival outcomes for the subgroups were as follows: for all patients, OS 20.9 months
and PFS 7.2 months; for those similar to eligible patients in the first-line ADAPT trial, OS 14.7 months and PFS 5.6 months; for
those similar to patients in first-line TIVO-1 trial, OS 24.8 months and PFS 8.2 months; for those similar to patients in second-line
INTORSECT trial, OS 13.0 months and PFS 3.9 months; and for those similar to patients in the third-line GOLD trial, OS 18.0
months and PFS 4.4 months.
Conclusions: Patients who are able to receive more lines of TT live longer. Survival benchmarks provide context and perspective
when interpreting and designing clinical trials.
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The advent of targeted therapy (TT) has dramatically changed the
treatment paradigm and prognosis of metastatic renal cell
carcinoma (mRCC). Seven agents are now approved or available
for use in North America and Europe, and more are awaiting phase
III results (Figlin et al, 2012; ClinicalTrials.gov Identifier:
NCT01030783, NCT00664326, NCT01865747, NCT01136733,
NCT00303862, NCT01472081, NCT01582672). In the last 10
years, the standard of care for a patient with mRCC has undergone
multiple revisions, mainly due to the rapidity of emerging data
from prospective trials. There is a growing need for benchmark
survival data from real-life patients exposed to one or more of the
contemporary targeted therapies. Such data can provide guidance
for future prospective trials and set expectations for outcomes that
new therapies should exceed.
A number of retrospective studies have examined different
aspects of clinical experience with targeted therapies. The most
studied agents are anti-vascular endothelial growth factor (VEGF)
inhibitors, sunitinib and sorafenib, usually in the setting of
sequential therapy or following immunotherapy (Buchler et al,
2012; Harrison et al, 2013; Wahlgren et al, 2013). Retrospective
studies have been completed to investigate the optimal sequence of
TKIs and other second-line therapies such as mammalian target of
rapamycin (mTOR) inhibitors, as well as the timing of cytor-
eductive nephrectomy (Buchler et al, 2012; Giuliani and Drudi,
2012; Stenner et al, 2012; Stroup et al, 2013). A multicentre
Swedish study has previously found that in 2753 patients treated
from 2002 to 2008, the median overall survival (OS) was 9.6
months from 2002 to 2006, vs 12.4 months from 2006 to 2008
(Wahlgren et al, 2013). Given that the first targeted agent,
sunitinib, was approved in 2006, the clinical experience with TT in
this database had not matured, with a limited number of exposures
to multiple lines of contemporary agents. Another large cohort
study found the median OS of 18.8 months among those who were
treated with first-line VEGF-targeted treatment, although the
outcomes were reported in the context of prognostic model
validation (Heng et al, 2013).
The objectives of the study were two-fold: first, to compare the
survival outcomes of mRCC patients in the International mRCC
Database Consortium (IMDC) cohort who were treated with first,
second, third, or more lines of TT; second, to benchmark survival
outcomes based on the different inclusion criteria for selected phase
III trials of novel targeted agents. Our study evaluated the largest
multicentre retrospective database of patients who have mRCC and
have received one or more VEGF inhibitors or mTOR inhibitors over
a 9-year period. We also examined OS and progression-free survival
(PFS) of patients using inclusion criteria simulated from large phase
III trials, both published and recently reported studies.
MATERIALS AND METHODS
Twenty international cancer centres in Canada, the United States,
Japan, South Korea, Singapore, and Denmark provided data on
consecutive patients with mRCC. All patients were treated with
anti-VEGF TT for mRCC (sunitinib, sorafenib, bevacizumab,
pazopanib, and axitinib) and/or mTOR inhibitors (temsirolimus
and everolimus) between January 2004 and December 2012, either
per standard of care or as part of clinical trials. Patients were
allowed to have undergone previous immunotherapy, but only
targeted therapies were counted as lines of therapy used in each
patient. Patient lists were obtained in a consecutive fashion from
pharmacy or registry data in each centre, which included every
mRCC patient who received TT. Using uniform data templates, we
collected baseline patient characteristics and survival data from
medical chart reviews and publically available records. All centres
obtained local institutional ethics approval before including data in
the cohort.
We assessed the survival outcomes of patients who received only
one line of TT, who received two lines of targeted therapies, and
who received three or more targeted therapies. We then extracted
data and analysed survival outcomes for the following six sub-
groups based on recent large prospective trials of TT:
 All patients who received at least one TT;
 Patients who received first-line TT with an intermediate or poor
risk disease and whose diagnosis to treatment interval was less
than 1 year, similar to those enrolled in Phase 3 Trial of
Autologous Dendritic Cell Immunotherapy (AGS-003) Plus
Standard Treatment of Advanced Renal Cell Carcinoma
(ADAPT; ClinicalTrials.gov Identifier: NCT01582672);
 Patients who received first-line TT and previously underwent
nephrectomy, similar to those enrolled in A Study to Compare
Tivozanib (AV-951) to Sorafenib in Subjects With Advanced
Renal Cell Carcinoma (TIVO-1; ClinicalTrials.gov Identifier:
NCT01030783);
 Patients who received second-line TT after at least one other
VEGF- TT, similar to those enrolled in Temsirolimus Vs
Sorafenib As Second-Line Therapy In Patients With Advanced
RCC Who Have Failed First-Line Sunitinib (INTORSECT;
ClinicalTrials.gov Identifier: NCT00474786);
 All patients who received third-line therapy;
 Patients who received third-line TT and were previously exposed
to one VEGF inhibitor and one mTOR inhibitor, similar to those
enrolled in Study of Dovitinib Vs Sorafenib in Patients With
Metastatic Renal Cell Carcinoma (GOLD; ClinicalTrials.gov
Identifier: NCT01223027).
For each subgroup, we obtained the median OS and PFS,
calculated from the line of therapy under consideration unless
otherwise specified. We defined OS as the period between TT
initiation and date of death, unless it was censored on the day of
the last follow-up visit. We defined PFS as the period between
treatment initiation and progression, drug cessation, or death,
unless it was censored at the last follow-up visit. Progression was
assessed radiologically using the Response Evaluation Criteria in
Solid Tumors (RECIST), or clinically when continuation of
treatment was deemed futile (Eisenhauer et al, 2009).
Statistical analysis. Baseline patient and disease characteristics
were summarised using descriptive analysis. Overall survival and
PFS were estimated for each sub-cohort with a 95% confidence
interval (CI), and differences among the sub-cohorts were
adjusted by the known independent predictors of poorer OS
(KPS o80%, diagnosis to treatment interval o1 year, hypercal-
cemia, anemia, thrombocytosis, neutrophilia) using proportional
hazards regression (Heng et al, 2009). The statistical analyses
were performed using SAS version 9 (SAS Institute, Cary, NC,
USA), and Po0.05 (two-sided) was considered statistically
significant.
RESULTS
Patient and treatment characteristics. In total, 2705 patients
were included in the study cohort with a median follow-up period
of 37 months. Their baseline patient characteristics and therapies
are summarised in Table 1. One thousand five hundred and thirty
three patients (57%) received or are still receiving 1TT. The most
frequently used first-line therapy was sunitinib, used in 1959
patients (72%). This was followed by sorafenib in 474 patients
(18%) and bevacizumab in 109 patients (4%). Other first-line
choices included temsirolimus, pazopanib, everolimus, and axiti-
nib. In total, 734 patients (27%) received a total of two lines of
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therapy, whereas only 438 patients (16%) received three or more
lines of therapy.
Survival outcomes in the IMDC cohort. The median OS in
patients who received only one TT was 14.9 months from the time
of first-line therapy initiation (95% CI, 13.2–16.7 months), with
PFS of 6.7 months (95% CI, 5.9–7.5 months). In contrast, the
median OS in patients who received two lines of therapy was 21.0
months, measured from the time of first-line therapy initiation
(95% CI, 19.1–23.5 months), with PFS of 3.4 months, measured
from the time of second-line therapy initiation (95% CI, 3.0–3.9
months). Patients who received three or more lines of TT had an
OS of 39.2 months, measured from the time of first-line initiation
(95% CI, 36.3–41.9 months), with PFS of 4 months, measured from
the time of third-line therapy initiation (95% CI, 3.4–4.5 months).
On multivariable analysis, adjusting for the IMDC prognostic
criteria, receiving second-line or third-line therapy was indepen-
dently associated with better OS (HR¼ 0.738, 95% CI 0.663–0.821;
HR¼ 0.626, 95% CI 0.541–0.724, respectively, both Po0.0001).
Table 2 summarises the survival outcomes of the six subgroups,
as described above.
DISCUSSION
Survival benchmark studies provide context when designing and
interpreting new clinical trials. Outcomes from real-life cohorts
treated with current standard therapies serve as comparators for
future clinical trials, with the expectation that newer therapies will
perform better than the standard therapies. The benchmarked
outcomes can also allow for future statistical considerations such as
sample size for new prospective trials. Prior benchmark studies in
mRCC were limited to patients who received cytokine immu-
notherapy (Belldegrun et al, 2008). Since the initial Food and Drug
Administration (FDA) approval of sorafenib in 2005, contempor-
ary targeted therapies have now largely replaced immunotherapy
as the new standard of care. This study is, to the authors’
knowledge, the first and largest multi-national benchmarking study
to date of mRCC patients treated with at least one line of TT.
One of the limitations in our methodology is its retrospective
patient recruitment. Patients included in our cohort were not
selected on a certain criteria or hand-picked by each centre; rather,
they were derived from consecutive patient lists in pharmacy or
registry data. This strategy was employed to minimise inherent
selection bias, to reflect clinical practice as closely as possible, and
to include all patients receiving TT as part of standard-of-care or
clinical trials. The denominator for patients who received one line
of TT is unknown and may vary across centres. However, the
denominator for patients who received two lines of TT is, by
definition, patients who received one line of TT, and the
denominator for patients who received three lines of TT is patients
who received two lines of TT; this allows us to assess and compare
outcomes in sub-groups within our patient cohorts.
The study compares real-life retrospective survival outcomes
with those reported in prospective trials. Since the era of
immunotherapy, the median OS of patients in our study cohort,
from the time of first-line agent use, has doubled (Belldegrun et al,
2008). The outcomes are slightly inferior to, but still comparable
with, those reported in the updated sunitinib phase III study,
in the pazopanib phase III study, or those reported in TIVO-1
(summarised in Table 3) (Motzer et al, 2009; Sternberg et al, 2013).
This type of comparison is exploratory in nature. The small
difference is likely due to the difference in patient inclusion criteria,
with non-clear cell histology and patients with poor functional
status, brain metastases, and comorbidities in the real-life cohort,
who would have otherwise been excluded in clinical trials. The
results in our study, therefore, not only confirm and support the
findings in prospective trials, but are also generalisable to a wider,
more heterogeneous range of patients and clinical practices across
the centres.
In regards to the survival from the initiation of the second-line
therapy, the outcomes for patients who received second-line TT in
our cohort are comparable to the outcomes from the INTORSECT
and RECORD-1 trials, and only slightly inferior to the AXIS trial
(summarised in Table 3) (Motzer et al, 2008; Rini et al, 2011). The
outcomes for patients in our study who have received a third-line
TT after a TKI and an mTOR inhibitor, have exceeded the median
survival outcome of GOLD trial, for both the study and control
arms (summarised in Table 3). Trials for other novel therapies,
including lenvatinib, regorafenib, cediranib, AGS-003, cabozanti-
nib, and nivolumab, are ongoing or have preliminary results. The
survival outcomes in our study will serve as benchmark for these
studies.
In our study, sunitinib was the most popular first-line therapy,
but the diversity of first-line and second-line therapy choices
Table 1. Baseline patient characteristics
Characteristic Median or proportion %
Age (years) 61 (IQR 54–68)
Karnofsky performance status (%) 80 (IQR 80–90)
Non-clear cell carcinoma, n¼2532 309 (12%)
Sarcomatoid histology, n¼ 2312 231 (10%)
IMDC Prognostic Score, n¼2258
Favourable 431 (19%)
Intermediate 1243 (55%)
Poor 584 (26%)
First-line therapy, n¼2703
Sunitinib 1959 (72%)
Sorafenib 474 (18%)
Bevacizumab 109 (4%)
Temsirolimus 66 (2%)
Pazopanib 62 (2%)
Everolimus 22 (1%)
Axitinib 4 (o1%)
Other 7 (o1%)
Second-line therapy, n¼1175
Sorafenib 328 (28%)
Sunitinib 280 (24%)
Everolimus 269 (23%)
Temsirolimus 152 (13%)
Pazopanib 49 (4%)
Bevacizumab 45 (4%)
Immunotherapy 24 (2%)
Axitinib 20 (2%)
Cabozantinib 8 (o1%)
Third-line therapy, n¼460
Everolimus 99 (23%)
Sunitinib 79 (17%)
Temsirolimus 77 (17%)
Sorafenib 76 (17%)
Pazopanib 41 (9%)
Bevacizumab 33 (7%)
Clinical Trial 27 (6%)
Immunotherapy 17 (3%)
Axitinib 11 (2%)
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indicates that the sequence of TT prescription may be practice-
dependent. In addition, until recently, data from head-to-head trial
that tested the comparative effectiveness between front-line TKIs
were limited. The recently published COMPARZ study shows that
pazopanib was not inferior to sunitinib in terms of PFS as a first-
line option in mRCC (Motzer et al, 2013). Thus, the survival
advantage may be more associated with increasing lines of targeted
therapies given, rather than their sequence, which corresponds
with what was shown in prior studies (Motzer et al, 2008; Kirchner
et al, 2010).
Reflecting the above observation, patients in our study who
received more lines of therapy lived longer with longer PFS,
adjusting for prognostic factors. This finding is comparable with
results from randomised prospective second-line TT trials, which
demonstrated an increased PFS with the use of TT compared with
placebo (Motzer et al, 2008). Only 16% of the patients in our
study were exposed to three or more lines of TT. This is partly
explained by the 9-year study period that encompasses evolving
treatment paradigms. Some early years saw targeted therapies
offered only as trial drugs, and less than three targeted therapies
were approved or available in most participating centres until at
least 2008. Our study included a diverse range of patients many of
whom would have been excluded from clinical trials, and
therefore may not have had the opportunity to receive more
lines of therapy on a trial. On the other hand, the survival
advantage likely also stems from the inherent selection bias in a
retrospective cohort. Even with the currently approved regimens,
many patients die or become too ill to receive more than one or
two lines of therapy, especially if their diseases had unfavourable
prognostic indicators.
CONCLUSION
The current management of mRCC involves an evolving algorithm
with a goal to optimise the outcome for each individual patient
with as many lines of TT as the patient may benefit from.
We present long-term, multicentre data to provide an under-
standing of survival outcomes achievable with available therapeutic
agents. We demonstrate a prolonged survival with one or more TT
comparable with that of previous prospective trials. The results can
serve as a benchmark to compare the outcomes of emerging
treatment options and help shape the design of future trials with
realistic expectations of outcomes such as PFS.
Table 2. OS and PFS in the specified sub-cohorts using data from the IMDC (see Materials and Methods)
OS PFS
Groups
Number of
patients
Months
(95% CI)
Number of
patients
Months
(95% CI)
All patients receiving first-line TT 2705 20.9 (19.6–22.5) 2659 7.2 (6.7–7.7)
Patients receiving first-line TT with the following: 1189 14.7 (13.3–16.5) 1174 5.6 (5.3–6.1)
Intermediate or poor risk disease
Diagnosis to treatment interval o1 yeara
Similar to inclusion criteria per ADAPT
Patients receiving first-line TT, with prior nephrectomya 2117 24.8 (23.1–27.3) 2080 8.2 (7.8–8.6)
Similar to inclusion criteria per TIVO-1
Patients receiving second-line TT after at least one other TTb 1157 13.0 (12.2–14.7) 1151 3.9 (3.6–4.3)
Similar to inclusion criteria per INTORSECT
All patients receiving third-line therapyc 455 12.1 (10.7–13.9) 425 4.0 (3.4–4.5)
Patients receiving third-line therapy and previously exposed to at least one VEGF
inhibitor and one mTOR inhibitorc
147 18.0 (11.8–24.0) 140 4.4 (3.3–5.2)
Similar to inclusion criteria per GOLD
Abbreviations: OS¼overall survival; PFS¼progression-free survival; TT¼ targeted therapy.
aOS and PFS calculated from the time of first-line therapy initiation.
bOS and PFS calculated from the time of second-line therapy initiation.
cOS and PFS calculated from the time of third-line therapy initiation.
Table 3. Survival outcomes from phase III studies of first-, second-, and
third-line targeted therapies against an approved agent or placebo
OS PFS
First-line
Sunitinib phase III study
(sunitinib vs interferon alpha)
26.4 vs 21.8
months (P¼0.051)
11 vs 5 months
(Po0.001)
Pazopanib phase III study
(pazopanib vs placebo)
22.9 vs 20.5
months (P¼0.224)
9.2 vs 4.2 months
(Po0.0001)
TIVO-1 (tivozanib vs sorafenib) 28.8 vs 29.3
months (P¼0.105)
11.9 vs 9.1
months
(P¼0.042)
Second-line
RECORD-1 (everolimus vs
placebo)
13.57 vs 13.01
months (P¼0.23)
4.9 vs 1.87
months
(Po0.0001)
INTORSECT (temsirolimus vs
sorafenib)
16.64 vs 12.27
months (P¼0.01)
4.28 vs 3.91
months (P¼0.19)
AXIS (axitinib vs sorafenib) 20.1 vs 19.2
months (P¼0.37)
6.7 vs 4.7 months
(Po0.001)
Third-line
GOLD (dovitinib vs sorafenib) 11.1 vs 11.0
months (P¼0.357)
3.7 vs 3.6 months
(P¼0.063)
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